Exploring indication spaces for targets and compounds, for new ideas as well as for shelved projects or even for established drugs.
We assess the specific indication option space for your asset using big data analysis tools. We propose first positioning, indication expansion, repositioning, or repurposing building on our more than 10 years of experience. We identify the most suited proof-of-concept indication for your asset. We propose feasible paths forward by identifying the most translational in vivo or ex vivo models for your selected indication. We have as well a broad track record of projects that found their home in oftentimes unexpected indications. We perform in silico-, in vivo-, ex vivo-, and in vitro-studies for you in our labs - or we orchestrate your studies with third partners. We assist you from conceptual drafting to clinical translation and regulatory documentation by de-risking every step.
We offer in silico analyses including broad literature and patent review in a first screening approach and in-depth assessments of selected indications. Text mining, signaling pathway- and mode-of-action analyses are used to figure out the most compelling scientific rationale for optimal positioning of your asset in the disease landscape.
Availability assessment of preclinical models and their translatability into the clinical situation will guide you to the right path forward. We help you to rigorously assess your asset by head to head comparison with standard of care medications and competitor pipeline compounds.
We build on our long-term experience in a wide variety of pharmacodynamic or disease models from various fields of indications such as
We smartly combine our in-house disease model repertoire with external model expertise to guarantee you outstanding preclinical de-risking programs for your asset.